Collapse to view only § 2001. Designation of United States Anti-Doping Agency
- § 2001. Designation of United States Anti-Doping Agency
- § 2002. Records, audit, and report
- § 2003. Authorization of appropriations
- § 2004. Information sharing
§ 2001. Designation of United States Anti-Doping Agency
(a) Definitions
In this subchapter:
(1) United States Olympic Committee
(2) Amateur athletic competition
(3) Amateur athlete
(b) In general
The United States Anti-Doping Agency shall—
(1)
(A) serve as the independent anti-doping organization for the amateur athletic competitions recognized by the United States Olympic and Paralympic Committee;
(B) be responsible for certifying in advance any testing conducted by international organizations under the World Anti-Doping Code for international amateur athletes and athletic competitions occurring within the jurisdiction of the United States; and
(C) be recognized worldwide as the independent national anti-doping organization for the United States;
(2) ensure that athletes participating in amateur athletic activities recognized by the United States Olympic Committee are prevented from using performance-enhancing drugs or prohibited performance-enhancing methods adopted by the Agency;
(3) implement anti-doping education, research, testing, and adjudication programs to prevent United States Amateur Athletes participating in any activity recognized by the United States Olympic Committee from using performance-enhancing drugs or prohibited performance-enhancing methods adopted by the Agency;
(4) serve as the United States representative responsible for coordination with other anti-doping organizations coordinating amateur athletic competitions recognized by the United States Olympic Committee to ensure the integrity of athletic competition, the health of the athletes, and the prevention of use by United States amateur athletes of performance-enhancing drugs or prohibited performance-enhancing methods adopted by the Agency; and
(5) promote a positive youth sport experience by using a portion of the funding of the United States Anti-Doping Agency to provide educational materials on sportsmanship, character building, and healthy performance for the athletes, parents, and coaches who participate in youth sports.
(c) Due process in arbitration proceedings
(Pub. L. 109–469, title VII, § 701, Dec. 29, 2006, 120 Stat. 3533; Pub. L. 113–280, § 2
§ 2002. Records, audit, and report
(a) Records
(b) Report
The United States Anti-Doping Agency shall submit an annual report to Congress which shall include—
(1) an audit conducted and submitted in accordance with section 10101 of title 36; and
(2) a description of the activities of the agency.
(Pub. L. 109–469, title VII, § 702, Dec. 29, 2006, 120 Stat. 3534.)
§ 2003. Authorization of appropriations
There are authorized to be appropriated to the United States Anti-Doping Agency—
(1) for fiscal year 2023, $15,500,000;
(2) for fiscal year 2024, $16,200,000;
(3) for fiscal year 2025, $16,900,000;
(4) for fiscal year 2026, $17,700,000;
(5) for fiscal year 2027, $18,500,000;
(6) for fiscal year 2028, $19,800,000;
(7) for fiscal year 2029, $22,100,000;
(8) for fiscal year 2030, $24,900,000; and
(9) for fiscal year 2031, $23,700,000.
(Pub. L. 109–469, title VII, § 703, Dec. 29, 2006, 120 Stat. 3534; Pub. L. 113–280, § 3, Dec. 18, 2014, 128 Stat. 3020; Pub. L. 117–103, div. Q, title III, § 304, Mar. 15, 2022, 136 Stat. 817.)
§ 2004. Information sharing
Except as otherwise prohibited by law and except in cases in which the integrity of a criminal investigation would be affected, pursuant to the obligation of the United States under Article 7 of the United Nations Educational, Scientific, and Cultural Organization International Convention Against Doping in Sport done at Paris October 19, 2005, and ratified by the United States in 2008, the Attorney General, the Secretary of Homeland Security, and the Commissioner of Food and Drugs shall provide to the United States Anti-Doping Agency any relevant information relating to the prevention of the use of performance-enhancing drugs or the prohibition of performance-enhancing methods.
(Pub. L. 117–103, div. Q, title III, § 305, Mar. 15, 2022, 136 Stat. 817.)